About AIT Therapeutics (OTCMKTS:AITB)
AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company's pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis (RSV), cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections. The company was founded in 2011 and is based in Ness Ziona, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AITB
CUSIPN/A
Phone972-8684-3313
Debt
Debt-to-Equity RatioN/A
Current Ratio1.38%
Quick Ratio1.38%
Price-To-Earnings
Trailing P/E Ratio-1.00
Forward P/E Ratio-3.30
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.37) per share
Price / Book-2.19
Profitability
EPS (Most Recent Fiscal Year)($3.01)
Net Income$-18,040,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-377.29%
Miscellaneous
Employees12
Outstanding Shares8,400,000
AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions
What is AIT Therapeutics' stock symbol?
AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."
How were AIT Therapeutics' earnings last quarter?
AIT Therapeutics (OTCMKTS:AITB) posted its quarterly earnings data on Monday, March, 19th. The company reported ($0.28) EPS for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.22. View AIT Therapeutics' Earnings History.
What price target have analysts set for AITB?
3 Wall Street analysts have issued 12 month target prices for AIT Therapeutics' stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate AIT Therapeutics' stock price to reach $16.00 in the next twelve months. View Analyst Ratings for AIT Therapeutics.
Who are some of AIT Therapeutics' key competitors?
Some companies that are related to AIT Therapeutics include Neovasc (NVCN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), Interpace Diagnostics Gr (IDXG), Valeritas (VLRX), Cytori Therapeutics (CYTX), InVivo Therapeutics (NVIV), Alliqua BioMedical (ALQA), Neurometrix (NURO), Amedica (AMDA), STRATA Skin Sciences (SSKN), Avinger (AVGR), TearLab (TEAR) and Lombard Medical Technologies (EVARF).
Who are AIT Therapeutics' key executives?
AIT Therapeutics' management team includes the folowing people:
- Mr. Steven Adam Lisi, Chairman & Chief Exec. Officer (Age 47)
- Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 44)
- Mr. David Grossman, Sec. and Director (Age 43)
- Mr. Haim Aviv, Chief Financial Officer (Age 36)
- Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
Has AIT Therapeutics been receiving favorable news coverage?
Headlines about AITB stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AIT Therapeutics earned a news sentiment score of 0.17 on Accern's scale. They also gave media coverage about the company an impact score of 45.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are AIT Therapeutics' major shareholders?
How do I buy shares of AIT Therapeutics?
Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AIT Therapeutics' stock price today?
One share of AITB stock can currently be purchased for approximately $3.00.
How big of a company is AIT Therapeutics?
AIT Therapeutics has a market capitalization of $25.19 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.
How can I contact AIT Therapeutics?
AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.
MarketBeat Community Rating for AIT Therapeutics (AITB)
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
AIT Therapeutics (OTCMKTS:AITB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for AIT Therapeutics in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 433.33%. The high price target for AITB is $16.00 and the low price target for AITB is $16.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $16.00 | $16.00 | $16.00 | $15.00 |
| Price Target Upside: | 433.33% upside | 185.71% upside | 185.71% upside | 160.87% upside |
AIT Therapeutics (OTCMKTS:AITB) Consensus Price Target History
AIT Therapeutics (OTCMKTS:AITB) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 12/2/2017 | Roth Capital | Set Price Target | Buy | $16.00 |  |
| 8/24/2017 | Laidlaw | Initiated Coverage | Buy -> Buy | $16.00 | |
| 8/7/2017 | Ladenburg Thalmann | Initiated Coverage | Buy | | |
(Data available from 4/22/2016 forward)
AIT Therapeutics (OTCMKTS:AITB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AIT Therapeutics (OTCMKTS AITB) Insider Trading and Institutional Ownership History
AIT Therapeutics (OTCMKTS AITB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
AIT Therapeutics (OTCMKTS AITB) News Headlines
| Source: |
|
AIT Therapeutics (OTCMKTS:AITB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
AIT Therapeutics (OTCMKTS AITB) Stock Chart for Sunday, April, 22, 2018
Loading chart…
